Table 2.
Ongoing clinical trials of the vaccination in glioblastoma.58
| Trail code | Disease | WHO grade | Vaccine | Phase | Start time | Status |
|---|---|---|---|---|---|---|
| NCT01967758 | rAA, rGBM | Grade III, IV | ADU-623 | Phase I | 2013 | Recruiting participants |
| NCT00905060 | nGBM | Grade IV | HSPPC-96 | Phase II | 2009 | Completed |
| NCT02122822 | nGBM | Grade IV | HSPPC-96 | Phase I | 2013 | Ongoing, but not recruiting participants |
| NCT02722512 | Newly diagnosed or recurrent pediatric HGG, ependymoma | — | HSPPC-96 | Phase I | 2016 | Recruiting participants |
| NCT01814813 | rGBM | Grade IV | HSPPC-96 | Phase II | 2013 | Recruiting participants |
| NCT03018288 | nGBM | Grade IV | HSPPC-96 | Phase II | 2017 | Recruiting participants |
| NCT02454634 | nAA, nAO, nGBM | Grade III, IV | Derived from IDH1 R132H | Phase I | 2015 | Recruiting participants |
| NCT02960230 | Newly diagnosed DIPG, newly diagnosed glioma | — | K27M peptide | Phase I | 2016 | Recruiting participants |
| NCT02455557 | nGBM | Grade IV | SurVaxM | Phase II | 2015 | Recruiting participants |
| NCT00045968 | nGBM | Grade IV | DCs vaccine (DCVax) | Phase III | 2006 | Ongoing, but not recruiting participants |
| NCT02146066 | nGBM, rGBM | Grade IV | DCs vaccine (DCVax) | Expanded access | 2014 | Currently available |
| NCT00890032 | rGBM | Grade IV | DCs vaccine (brain tumor stem cells mRNA loaded) | Phase I | 2009 | Completed |
| NCT01171469 | rAA, rGBM, recurrent medulloblastoma, recurrent ependymoma | — | DCs vaccine (brain tumor stem cells as antigen) | Phase I | 2010 | Completed |
| NCT02820584 | rGBM | Grade IV | DCs vaccine (tumor stem cell-loaded) | Phase I | 2016 | Not yet open |
| NCT01522820 | rGBM | Grade IV | DCs vaccine (fusion peptide loaded) | Phase I | 2012 | Completed |
| NCT02709616 | nGBM | Grade IV | DCs vaccine (tumor mRNA loaded) | Phase I/II | 2016 | Recruiting participants |
| NCT00639639 | nGBM | Grade IV | DCs vaccine (pp65 RNA loaded) | Phase I | 2006 | Ongoing, but not recruiting participants |
| NCT02465268 | nGBM | Grade IV | DCs vaccine (pp65 RNA loaded) | Phase II | 2016 | Recruiting participants |
| NCT02366728 | nGBM | Grade IV | DCs vaccine (pp65 RNA loaded) | Phase II | 2015 | Recruiting participants |
| NCT01567202 | nGBM, rGBM | Grade IV | DCs vaccine (autogeneic glioma stem-like cells (A2B5+) loaded) | Phase II | 2012 | Recruiting participants |
| NCT01204684 | nAA, rAA, nAO, rAO, nGBM, rGBM | Grade III, IV | DCs vaccine (tumor lysate loaded) | Phase II | 2010 | Ongoing, but not recruiting participants |
| NCT00626483 | nGBM | Grade IV | DCs vaccine (RNA loaded) | Phase I | 2007 | Ongoing, but not recruiting participants |
| NCT01957956 | nGBM | Grade IV | DCs vaccine (tumor lysate loaded) | Phase I | 2013 | Recruiting participants |
| NCT02049489 | rGBM | Grade IV | DCs vaccine (peptide loaded) | Phase I | 2016 | Ongoing, but not recruiting participants |
| NCT02649582 | nGBM | Grade IV | DCs vaccine (Wilms' tumor 1 mRNA loaded) | Phase I/II | 2015 | Recruiting participants |
| NCT01808820 | rAA, rGBM | Grade III, IV | DCs vaccine + tumor lysate boost | Phase I | 2013 | Recruiting participants |
| NCT02010606 | nGBM, rGBM | Grade IV | DCs vaccine (allogenic GBM stem-like cell lysate loaded) | Phase I | 2013 | Recruiting participants |
| NCT03014804 | rGBM | Grade IV | DCs vaccine (tumor lysate loaded)+ nivolumab | Phase II | 2017 | Not yet open |
| NCT01400672 | Recurrent brain stem GBM | Grade IV | Tumor lysate vaccine | Phase I | 2012 | Completed |
| NCT01759810 | rGBM | Grade IV | HSCs, DCs vaccine, CTLs | Phase II/III | 2012 | Enrolling by invitation |
| NCT02754362 | rGBM | Grade IV | TAA, Poly-ICLC, KLH, bevacizumab | Phase II | 2016 | Not yet open |
| NCT02078648 | rGBM | Grade IV | SL-701, poly-ICLC, bevacizumab | Phase I/II | 2014 | Ongoing, but not recruiting participants |
| NCT02546102 | nGBM | Grade IV | ICT-107 | Phase III | 2015 | Recruiting participants |
| NCT01920191 | nGBM | Grade IV | IMA950, Poly ICLC | Phase I/II | 2013 | Completed |
| NCT01222221 | nGBM | Grade IV | IMA950, GM-CSF | Phase I | 2010 | Completed |
| NCT02510950 | nGBM | Grade IV | Personalized peptide vaccine, Poly ICLC | Phase 0 | 2015 | Recruiting participants |
Notes: nGBM: newly diagnosed glioblastoma multiforme; rGBM: recurrent glioblastoma multiforme; nAA: newly diagnosed anaplastic astrocytoma; rAA: recurrent anaplastic astrocytoma; nAO: newly diagnosed anaplastic oligodendroglioma; rAO: recurrent anaplastic oligodendroglioma; HGG: high-grade glioma; TAA: tumor-associated antigen.